Aduhelm approval could signal new era for CNS drugs; analystsThe unexpected approval and lofty pricing of Biogen’s Alzheimer’s therapy Aduhelm is clearly the biopharma event of the Share XAduhelm approval could signal new era for CNS drugs; analystshttps://pharmaphorum.com/news/aduhelm-approval-could-signal-new-era-for-cns-drugs-analysts/
Intra-Cellular ends year with OK for schizophrenia drug lumateperoneUS biotech Intra-Cellular Therapies’ has claimed an FDA approval for schizophrenia therapy lumateperone setting up the launch of Share XIntra-Cellular ends year with OK for schizophrenia drug lumateperonehttps://pharmaphorum.com/news/intra-cellular-ends-year-with-ok-for-schizophrenia-drug-lumateperone/
